Related Experiment Video
Updated: Jul 2, 2026
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
153Sm: its use in multiple myeloma and report of a clinical experience
Elisabetta Abruzzese1, Francesco Iuliano, Malgorzata Monika Trawinska
1Tor Vergata University, S. Eugenio Hospital, Hematology, P.le dell'Umanesimo 10, 00144 Rome, Italy. elisabetta.abruzzese@uniroma2.it
Background:
In the past years the bone seeking radiopharmaceutical samarium lexidronam ((153)Sm-EDTMP) has been increasingly used alone or in conjunction with chemotherapy and/or bisphosphonates for the treatment of painful bone metastasis.
Objective:
Its use has been explored in different solid tumours. In this report we explore its interesting characteristics and describe our experience in multiple myeloma (MM).
Methods:
(153)Sm-EDTMP has an affinity for bone and concentrates in areas of bone turnover. It decays as a therapeutic beta-emission and at the same time as gamma-photon that can be used for tracking its concentration with bone scan imaging. Ten patients with symptomatic MM were treated to achieve pain control.
Results:
Encouraging results were obtained in MM patients. The use of this radioisotope could be largely improved.
